PHARMA GUILLAUME
ActivePHARMA GUILLAUME has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €222k and a net result of €80k. Equity is growing by ~45.2% per year across the filed fiscal years. Its solvency ranks better than 19% of 10242 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability100=
Solvency11▲+3
Growth78=
Stability100
Bankruptcy probability, 12 months
0.8%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €10k at 30 days only on tighter terms
Liquidity short (current ratio 0.73 against 0.7 in 2024), and 90.6% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
9.4%
Return on assets
3.4%
Age of the figures
8 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 10242 sector peers (2025).
NBB · sector comparisonPosition among 10242 sector peers
Solvency
better than 19%
← weakest
strongest →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-08-2026, 26 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
26 d late
2024
29 d late
2023
27 d late
2022
61 d early
2021
25 d late
2020
23 d late
2019
19 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
15-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€80k▼ 24.4%
2024 · €106k
2018: €-37k
2019: €-34k
2020: €28k
2021: €22k
2022: €56k
2023: €69k
2024: €106k
2018 → 2025
Working capital
€-194k▲ 12.8%
2024 · €-222k
2018: €-222k
2019: €-281k
2020: €-314k
2021: €-370k
2022: €-365k
2023: €-315k
2024: €-222k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-90k-€-34k▲ 62.6%€35k€141k▲ 303%€222k▲ 56.8%
Operating result€64k-€144k▲ 124%€163k▲ 13.1%€209k▲ 28.5%€175k▼ 16.2%
Net result€22k-€56k▲ 156%€69k▲ 21.9%€106k▲ 54.5%€80k▼ 24.4%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 16% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.35M
Fixed assets
€1.82M▼ 7.0%
Current assets
€529k▲ 0.5%
Equity and liabilities €2.35M
Equity
€222k▲ 56.8%
Debt
€2.13M▼ 9.1%
The debt ratio falls from 94.3% to 90.6%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€339k▼
2024 · €378k
Cash flow
€244k▼
2024 · €276k
Solvency
9.4%▲
2024 · 5.7%
Current ratio
0.73▲
2024 · 0.70
Quick ratio
0.57▲
2024 · 0.52
Debt / equity
9.61▼
2024 · 16.58
ROE
36.2%▼
2024 · 75.2%
ROA
3.4%▼
2024 · 4.3%
Interest coverage
10.29▼
2024 · 10.38
Debt
€2.13M▼
2024 · €2.34M
Debt ≤ 1 year
€722k▼
2024 · €748k
Debt > 1 year
€1.41M▼
2024 · €1.59M
Income taxes
€62k▼
2024 · €67k
Staff costs
€131k▲
2024 · €129k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€2.49M€2.35M▼
Fixed assets21/28€1.96M€1.82M▼
Intangible fixed assets21€603k€517k▼
Tangible fixed assets22/27€1.36M€1.31M▼
Land and buildings22€1.17M€1.15M▼
Plant, machinery and equipment23€7k€4k▼
Furniture and vehicles24€178k€148k▼
Current assets29/58€526k€529k▲
Stocks and contracts in progress3€135k€118k▼
Stocks30/36€135k€118k▼
Amounts receivable within one year40/41€154k€187k▲
Trade receivables40€153k€136k▼
Other amounts receivable41€439€50k▲
Cash at bank and in hand54/58€236k€223k▼
Deferred charges and accrued income490/1€1k€1k▲
Equity and liabilities
Total equity and liabilities10/49€2.49M€2.35M▼
Equity10/15€141k€222k▲
Contributions10/11€19k€19k=
Reserves13€123k€203k▲
Non-distributable reserves130/1€120€120=
Reserves not available under the articles1311€120€120=
Distributable reserves133€123k€203k▲
Amounts payable17/49€2.34M€2.13M▼
Amounts payable after more than one year17€1.59M€1.41M▼
Financial debts170/4€1.59M€1.41M▼
Amounts payable within one year42/48€748k€722k▼
Current portion of amounts payable after more than one year42€183k€188k▲
Trade debts44€173k€155k▼
Suppliers440/4€173k€155k▼
Taxes, remuneration and social security45€57k€114k▲
Taxes450/3€44k€92k▲
Remuneration and social security454/9€14k€22k▲
Other amounts payable47/48€334k€265k▼
Accrued charges and deferred income492/3€2k-
Income statement
Code20242025
Remuneration, social security and pensions62€129k€131k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€169k€164k▼
Other operating charges640/8€10k€10k▲
Non-recurring operating charges66A€68-
Gross operating margin9900€517k€480k▼
Operating profit (loss)9901€209k€175k▼
Financial income75/76B€645€287▼
Recurring financial income75€645€287▼
Financial charges65/66B€36k€33k▼
Recurring financial charges65€36k€33k▼
Profit (loss) for the period before taxes9903€173k€143k▼
Income taxes67/77€67k€62k▼
Profit (loss) for the period9904€106k€80k▼
Profit (loss) for the period to be appropriated9905€106k€80k▼
Appropriation of the result
Profit (loss) to be appropriated9906€106k€80k▼
Transfer to equity691/2€106k€80k▼
To other reserves6921€106k€80k▼
Social balance
Average headcount (FTE)90872.42.6▲
The notes to these accounts (11 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
26-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 26 days late
05-08
State Gazette act
Registered office · Resignations & appointmentsGeneral meeting · Director resignation · Director appointment6 facts ▸
State Gazette act
Registered office · Resignations & appointments
General meeting · Director resignation · Director appointment6 facts ▸
- General meeting, 01/07/2026
- Director resignation, Michel GUILLAUME (administrateur et gestion journalière)
- Director appointment, Régis LANOVE (administrateur)
- Director appointment, Thibault DEHAES (administrateur)
- Registered-office move, rue E. Dinot 32 à 5590 Ciney
- Auditor appointment, Callens, Vandelanotte & Theunissen SRL
2025
31-12
Financial
Equity above €200kEq €222k ▲56.8%
6 profitable years in a row build equity to €222k.
29-08
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 29 days late
2024
31-12
Financial
Highest result since 2018net €106k ▲54.5%
Operating result €209k, net result €106k, both a record.
31-12
Financial
Equity above €100kEq €141k ▲303%
5 profitable years in a row build equity to €141k.
27-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 27 days late
2023
31-05
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
25-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 25 days late
2021
23-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 23 days late
2020
31-12
Financial
Back to profitnet €28k
Net result €28k after 2 loss-making years.
19-08
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 19 days late
2019
30-12
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 152 days late
2018
27-09
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 58 days late
2017
22-12
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 144 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 directors, no change since 2026
Régis Lanove
CurrentDirector · since 01-07-2026
Thibault DEHAES
CurrentDirector · since 01-07-2026
01-07-2026
Régis Lanove: Appointed as Director
01-07-2026
Thibault DEHAES: Appointed as Director
30-06-2026
Michel GUILLAUME: Resigned as Administrateur et gestion journalière
Location & real-estate footprint
Registered office, Ciney · 1 establishment unit since 2016
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue Edouard Dinot 325590 CineyGround area
4,534 m²
Building footprint
129 m²
Volume, LiDAR
1,212 m³
2 parcels, Wallonia · tallest building 11.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
PHARMA GUILLAUME
since 20162.253.931.392
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 91030D0007/00N003 | Wallonia | 4,240 m² | - | - |
| 56030C0572/00A000 | Wallonia | 294 m² | 1 · 129 m² | 11.9 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Statutory auditor
1 auditor| Callens, Vandelanotte & Theunissen SRLCurrent Auditor | 05-08-2026 → present |
Structure & network
Connections & network
5 connected companiesLinked via shared directors
viaRégis Lanove · Director
→
viaRégis Lanove · Director
→
viaRégis Lanove · Director
former→
viaRégis Lanove · Persoon belast met het dagelijks bestuur
former→
Show 1 more companies with a shared director
viaRégis Lanove · Director
former→
Recognitions · licences · registrations
Food safety, FASFC
1 siteThuin2.253.931.392
Similar companies · same sector, comparable size
Apothekers MARIABURG Ekeren
BE 0429.997.634
Antwerpen · Eq €222k
APOTHEEK VAN WAMBEKE
BE 0888.222.961
Oudenaarde · Eq €222k
Apotheek A. Meyers
BE 0416.590.056
Landen · Eq €222k
ACE PHARMA
BE 0436.322.331
Fexhe-le-Haut-Clocher · Eq €222k
APOTHEEK CLIJSTERS
BE 0462.486.201
Pelt · Eq €221k
Of 5,209 companies in sector 47730 we hold annual accounts for 3,851. 3,541 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded10-06-2016
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 10 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.